WO2015011653A9 - pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM - Google Patents

pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM Download PDF

Info

Publication number
WO2015011653A9
WO2015011653A9 PCT/IB2014/063336 IB2014063336W WO2015011653A9 WO 2015011653 A9 WO2015011653 A9 WO 2015011653A9 IB 2014063336 W IB2014063336 W IB 2014063336W WO 2015011653 A9 WO2015011653 A9 WO 2015011653A9
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
pharmaceutical dosage
polymeric pharmaceutical
particles
oral polymeric
Prior art date
Application number
PCT/IB2014/063336
Other languages
French (fr)
Other versions
WO2015011653A1 (en
Inventor
Pierre P D KONDIAH
Viness Pillay
Yahya Essop Choonara
Girish Modi
Pradeep Kumar
Lisa Claire Du Toit
Lomas K TOMAR
Charu TYAGI
Original Assignee
University Of The Witwatersrand, Johannesburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of The Witwatersrand, Johannesburg filed Critical University Of The Witwatersrand, Johannesburg
Publication of WO2015011653A1 publication Critical patent/WO2015011653A1/en
Publication of WO2015011653A9 publication Critical patent/WO2015011653A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)

Abstract

The disclosure relates to a pH responsive oral polymeric pharmaceutical dosage form for site specific delivery of a pharmaceutically active ingredient to a target site in a human or animal body, the dosage form comprising CHT-PEGDMA-MAA (chitosan-poly(ethylene glycol) dimethacrylate-methacrylic acid) co-polymer particles. In use exposure of the dosage form to media of increasing pH facilitates swelling of the particles, and exposure of the dosage form to media of decreasing pH facilitates constriction and/or aggregation of the particles.
PCT/IB2014/063336 2013-07-23 2014-07-23 pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM WO2015011653A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2013/05584 2013-07-23
ZA201305584 2013-07-23

Publications (2)

Publication Number Publication Date
WO2015011653A1 WO2015011653A1 (en) 2015-01-29
WO2015011653A9 true WO2015011653A9 (en) 2015-11-26

Family

ID=51582442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/063336 WO2015011653A1 (en) 2013-07-23 2014-07-23 pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM

Country Status (1)

Country Link
WO (1) WO2015011653A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201511284D0 (en) * 2015-06-26 2015-08-12 Univ Witwatersrand Jhb An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
US20210275440A1 (en) * 2016-09-29 2021-09-09 The University Of Memphis Research Foundation Microbead compositions and methods for delivering an agent
CN110256705B (en) * 2019-06-20 2021-12-17 中国科学院海洋研究所 PH response type polymer film and preparation method thereof

Also Published As

Publication number Publication date
WO2015011653A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
EP4233978A3 (en) Oral delivery of active drug substances
JP2014240439A5 (en)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
NZ714963A (en) Compositions and methods for treating anemia
GB2495676A (en) Use of binders for manufacturing storage stable formulations
MX354416B (en) Nalbuphine-based formulations and uses thereof.
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP2012136529A5 (en)
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
UA118576C2 (en) Pharmaceutical composition comprising brinzolamide
PH12015500823A1 (en) Modified release formulations for oprozomib
EP3162804A8 (en) New benzodiazepine derivative and use thereof
EA201400737A1 (en) DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE
WO2016040814A3 (en) Disulfide polymers and methods of use
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
FR2999086B1 (en) ORAL AND / OR ORAL COMPOSITION IN FINE FILM FORM OF A LOW SOLUBLE ACTIVE INGREDIENT, PROCESS FOR PREPARING THE SAME AND USE THEREOF
FR2996838B1 (en) PROCESS FOR THE PREPARATION OF A TITANIUM AND NIOBIUM MIXED OXIDE BY SOLVOTHERMAL TREATMENT; ELECTRODE AND LITHIUM ACCUMULATOR COMPRISING SAID MIXED OXIDE
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
MX2015009891A (en) Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy.
WO2014075203A1 (en) Nanoparticles with biodegradable and biocompatible polymer plga, loaded with the drug for human use pentoxifylline

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14771379

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 14771379

Country of ref document: EP

Kind code of ref document: A1